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Background
Disseminated intravascular coagulation (DIC) is characterized by platelet and neutrophil 
activation. Platelets are the major source of circulating vascular endothelial growth factor 
(VEGF). Endostatin, an anti-angiogenic factor, is a fragment of collagen that is released 
from the extracellular matrix via the active cleavage of neutrophil elastase, thereby increas-
ing the circulating level of endostatin. Hypercoagulable conditions such as DIC may in-
duce the release of VEGF and neutrophil elastase from the platelets and neutrophils.
Methods
We enrolled 240 patients who were clinically suspected of having DIC. Plasma levels of 
VEGF, endostatin, and neutrophil elastase were determined using commercial ELISA kits. 
Patients were diagnosed as having overt DIC if the cumulative International Society on 
Thrombosis and Haemostasis Subcommittee score was ＞5.
Results
Overt DIC was diagnosed in 80 of the 240 patients. The circulating VEGF and neutrophil 
elastase levels gradually increased according to the severity of coagulopathy, as reflected 
by the DIC score. However, the circulating endostatin level did not change significantly 
according to the DIC score. We divided the patients into 2 groups: the non-cancer and 
cancer patient groups, to exclude the VEGF release from tumor tissues. Interestingly, in 
non-cancer patients, higher VEGF and neutrophil elastase levels were found to be sig-
nificant diagnostic markers for overt DIC. 
Conclusion
Our findings suggest that circulating VEGF and neutrophil elastase levels are laboratory 
markers reflecting coagulation activity. They are expected to be potential diagnostic mark-
ers of overt DIC, especially in non-cancer patients.
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INTRODUCTION
  Disseminated intravascular coagulation (DIC) is charac-
terized by the widespread activation of the coagulation proc-
ess, which results in the formation of intravascular fibrin 
[1]. There is no laboratory test that can be reliably used 
for the definite diagnosis of DIC. The International Society 
of Thrombosis and Haemostasis (ISTH) subcommittee on 
DIC has proposed laboratory criteria for overt DIC [2]. These 
laboratory criteria for calculating the overt DIC score in-
cluded platelet count, a fibrin-related marker level, pro-
thrombin time (PT), and fibrinogen activity. 
  In DIC, high levels of thrombin and many inflammatory 
cytokines are generated; this leads to the activation of 
platelets. Platelet activation has been shown to result in 
the release of numerous angiogenic factors, including vas-
cular endothelial growth factor (VEGF), basic fibroblast 
growth factor, hepatocyte growth factor, angiopoietin-1, in-
sulin-like growth factor-1, epidermal growth factor, and pla-
telet-derived growth factor [3]. Among these angiogenic fac-Korean J Hematol 2010;45:23-8.
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Table 1. Characteristics of the study population.
All 
(n=240)
No overt DIC
(n=160)
Overt DIC 
(n=80)
P-value
Age, yrs
a) 58
(43-67)
59 
(43-67)
56 
(46-67)
0.520 
Gender, n (%) 0.124 
Male 146 
(60.8)
103 
(64.4)
43 
(53.8)
Female 94 
(39.2)
57 
(35.6)
37 
(46.2)
Clinical diagnosis,
n (%)
0.051 
Sepsis/severe 
infection
25 
(10.4%)
12 
(7.5%)
13 
(16.3%)
Malignancies 112 
(46.7%)
75 
(46.9%)
37 
(46.3%)
Hepatic failure 23 
(9.6%)
15 
(9.4%)
8 
(10.0%)
Trauma 20 
(8.3%)
17 
(10.6%)
3 
(3.8%)
Vascular
abnormalities
8 
(3.3%)
3 
(1.9%)
5
(6.3%)
Other
b) 52 
(21.7%)
38 
(23.8%)
14
(17.5%)
a)The values are presented as the median with interquartile range in
parentheses, 
b)Other clinical diagnosis included neurological 
diseases (spinal stenosis, meningeal disease, and cranial infarct), 
respiratory diseases (asthma, asphyxia, and chronic obstructive 
pulmonary disorder), coronary artery diseases, deep vein throm-
bosis, renal failure, diabetes, and benign prostate hyperplasia.
Abbreviation: DIC, disseminated intravascular coagulation.
tors, VEGF is a well-known angiogenic marker, and the 
levels of circulating VEGF have been shown to be a surrogate 
marker of angiogenic activity in various cancers and in-
flammatory diseases [4, 5]. 
  Neutrophil activation also occurs due to microcirculatory 
disturbance during DIC [6]. Upon the activation of neu-
trophils, neutrophil elastase is released from their cytoplas-
mic granules. Neutrophil elastase is a serine protease that 
can cleave many extracellular matrix proteins. Endostatin, 
an anti-angiogenic factor, is a C-terminal fragment of colla-
gen type XVIII, which can be released from the extracellular 
matrix via protease enzymes such as neutrophil elastase and 
cathepsin L [7, 8]. Therefore, it can be hypothesized that 
hypercoagulable conditions such as DIC may induce the 
release of VEGF and neutrophil elastase from platelets and 
neutrophils. The level of circulating endostatin can also be 
increased via the active cleavage by serine proteases such 
as neutrophil elastase. In this study, the levels of circulating 
VEGF, endostatin, and neutrophil elastase were investigated 
as possible diagnostic markers for overt DIC.
MATERIALS AND METHODS
1. Study population
  In all, 240 patients who were clinically suspected of having 
DIC were requested to undergo DIC screening battery tests 
and recruited for this study. Exclusion criteria were throm-
botic or bleeding disorders and warfarin or heparin medi-
cations within 3 days of blood collection. The characteristics 
of the patients, including their underlying disorders, are 
described in Table 1. Patients were diagnosed as having 
overt DIC if the cumulative score of the ISTH Sub committee 
scoring system was ＞5 [2]. We arbitrarily classified the 
patients who did not meet the criteria for overt-DIC (a cumu-
lative score of ＜5) as “no overt-DIC.”
2. Blood samples and assays
  Peripheral blood was collected in commercially available 
sodium citrate tubes (Becton Dickinson, San Jose, CA, USA). 
The whole blood samples were centrifuged for 15 min at 
1550 × g within 2 h after blood sampling. The prothrombin 
time and fibrinogen activity were determined by performing 
the standard clotting assay on a STA-R analyzer (Diagnostica 
Stago, Asnières, France). Plasma levels of VEGF, endostatin, 
and neutrophil elastase were determined using the following 
commercial ELISA kits: Quantikine human VEGF (R&D sys-
tems, Minneapolis, MN, USA), endostatin protein Accucyte 
(Oncogene Research Products, San Diego, CA, USA), and 
polymorphonuclear (PMN) elastase/α1-proteinase inhibitor 
complex (Oncogene Research Products), respectively. 
3. Statistical analysis
  All statistical analyses were carried out using statistical 
package for social sciences (SPSS) 12.0 for Windows (SPSS, 
Chicago, IL, USA). Continuous data comparisons were per-
formed using Mann-Whitney U and Kruskal-Wallis tests, 
and the relationships between categorical variables were 
compared using the chi-square test. The plasma levels of 
VEGF, endostatin, and neutrophil elastase were categorized 
into 2 groups according to the best cutoff values of diagnostic 
efficacy using MedCalc (MedCalc Software, Mariakerke, 
Belgium). Odds ratios (OR), as measures of the relative risk 
of distant metastasis, were estimated using multivariate logis-
tic regression analysis, and 95% confidence intervals (CI) 
were computed. Two-sided P-values of ＜0.05 were consid-
ered statistically significant.
RESULTS
  Overt DIC was diagnosed in 80 of the 240 patients accord-
ing to the ISTH diagnostic criteria. The characteristics of 
the patients were compared between the no overt DIC and 
overt DIC groups (Table 1). There were no differences with 
respect to age, gender, and clinical diagnosis between the 
no overt DIC and overt DIC patients. 
  To determine whether the levels of VEGF, endostatin, 
and neutrophil elastase correlated with coagulopathy, we 
divided the patients into 3 groups according to the DIC 
score. In all the patients, the serum level of VEGF increased 
as the DIC score increased (Fig. 1A). Because cancer tissues Korean J Hematol 2010;45:23-8.
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Fig. 1. Plasma VEGF, endostatin, and elastase levels based on the DIC score in total (A), cancer (B), and non-cancer (C) patients. The upper and lower 
limits of each box represent the value of 25 and 75 percentile, respectively, and the bar represents the range of the levels of analyte. DIC groups
I, II, and III included the patients with DIC score of 0-3, 4-5, and 6 or more, respectively. 
a)P＜0.05, 
b)P＜0.001. VEGF, vascular endothelial growth
factor; DIC, disseminated intravascular coagulation.
might show increased VEGF secretion, we separated 
non-cancer patients from cancer patients. Both in cancer 
and non-cancer patients, the level of VEGF correlated with 
the degree of coagulopathy (Fig. 1B, C). Similarly, the level 
of neutrophil elastase increased according to the DIC scores 
in all, cancer, and non-cancer patients. On the other hand, 
the level of endostatin showed no significant difference ac-
cording to the DIC scores. 
  Platelet count, a critical marker for the diagnosis of DIC, 
differed significantly between the no overt DIC and overt 
DIC groups (Table 2). The level of VEGF was higher in 
the overt DIC group than in the no overt DIC group in 
all (P＜0.001), cancer (P=0.016), and non-cancer patients 
(P=0.001). Similarly, the level of neutrophil elastase was 
higher in the overt DIC group than in the no overt DIC 
group, while that of endostatin showed no significant differ-
ence between the no overt DIC and overt DIC groups. 
  To assess the previously known and new potential markers 
for predicting overt DIC, we analyzed the OR of each parame-
ter for the diagnosis of overt DIC using logistic regression 
test (Table 3). The cutoff value for each parameter was defined 
by the points yielding the best diagnostic accuracy for overt 
DIC in the relative operating characteristic (ROC) curves. 
In univariate logistic regression analysis, decreased platelet Korean J Hematol 2010;45:23-8.
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Table 2. Comparison of plasma levels of VEGF, elastase, and endostatin in patients with and without overt DIC.
All patients Cancer patients Non-cancer patients
No overt 
DIC 
(n=160)
Overt 
DIC 
(n=80)
P-value
No overt 
DIC (n=75)
Overt 
DIC 
(n=37)
P-value
No overt 
DIC (n=85)
Overt 
DIC (n=43)
P-value
Platelet (×10
3/μL) ＜0.001 ＜0.001 ＜0.001
    Median 153.5 43.0 191.0 37.0 139.0 51.0
    IQR 89.5-248.5 28.0-79.0 107.0-271.0 26.5-61.8 81.0-231.0 28.0-91.0
VEGF (pg/mL) ＜0.001 0.016 0.001
    Median 83.2 149.7 69.7  127.7  88.8  217.2 
    IQR 55.5-142.9 68.9-296.6 50.1-116.2 62.9-191.2 64.7-164.6 71.0-401.4
Endostatin (ng/mL) 0.193 0.087 0.942
    Median 4.9 5.4 3.7  4.7  6.0 6.3 
    IQR 2.3-8.2 3.5-8.4 2.0-5.7 2.6-8.4 3.2-10.3 4.0-8.5
Elastase (ng/mL) ＜0.001 0.059 ＜0.001
    Median 75.7 179.6 53.9  92.0  124.7 402.8
    IQR 37.5-184.9 67.2-518.6 23.2-123.7 32.1-191.6 54.0-284.7 165.2-805.8
Abbreviations: IQR, interquartile range; VEGF, vascular endothelial growth factor; DIC, disseminated intravascular coagulation.
count, prolonged PT, and lower fibrinogen level were found 
to be related with the increased risk of overt DIC (OR for 
platelet, PT, and fibrinogen: in all patients: 16.00, 10.28, 
and 6.41, respectively; in cancer patients: 53.60, 8.47, 4.45, 
respectively; and in non-cancer patients: 9.40, 16.11, 11.51, 
respectively; P＜0.001 in each analysis). Among the new 
potential markers, higher levels of VEGF and neutrophil 
elastase were found to be good predictors of overt DIC in 
univariate analysis (OR of VEGF and neutrophil elastase: 
in all patients: 3.67 and 3.32, respectively; in cancer patients: 
3.47 and 2.83, respectively; and in non-cancer patients: 5.37 
and 7.86, respectively; P＜0.003 in each analysis).
  In multivariate analysis adjusted for patient’s age, sex, 
platelet count, PT, and fibrinogen level (Table 3), decreased 
platelet count and prolonged PT were found to be significant 
predictors of overt DIC (OR of platelet and PT: in all patients: 
18.42 and 7.95, respectively; in cancer patients: 96.48 and 
16.95, respectively; and in non-cancer patients: 5.40 and 
8.47, respectively; P＜0.003 in each analysis). A lower level 
of fibrinogen was a significant predictor in all cancer and 
non-cancer patients (OR, 2.16; P=0.048 in all patients; OR, 
3.69;  P=0.015 in non-cancer patients), but not in cancer 
patients. Among the new potential markers, a higher level 
of VEGF was a significant predictor in non-cancer patients. 
In non-cancer patients, the OR of VEGF (OR, 5.62) was 
comparable with that of platelet count (OR, 5.40). However, 
in cancer patients, the VEGF level did not show significant 
OR. Significant increase in neutrophil elastase level was ob-
s e r v e d  o n l y  i n  n o n - c a n c e r  p a t i e n t s  ( O R ,  4 . 4 2 ;  P=0.017). 
DISCUSSION
  This study showed that the levels of circulating VEGF 
and neutrophil elastase gradually increased according to the 
severity of coagulopathy as reflected by the DIC score. 
However, there was no difference in the circulating endo-
statin level according to the DIC scores. We also demon-
strated that the elevated circulating level of VEGF and neu-
trophil elastase were significant diagnostic markers of overt 
DIC, especially, in non-cancer patients. 
  VEGF, which is also known as vascular permeability factor, 
is one of the most pivotal angiogenic factors [9]. Circulating 
VEGF levels have been shown to be associated with poor 
prognosis of cancer and to be a surrogate marker of angiogenic 
activity in various cancers [4]. VEGF can also be elevated 
in various benign disorders because platelets, monocytes, 
and endothelial cells can release VEGF into the blood 
circulation. Platelets are a major source of soluble VEGF 
in the peripheral blood [10]. In our study, the level of circulat-
ing VEGF was elevated probably because of the activation 
of platelets during ongoing coagulopathy. We divided the 
total patient population into the following 2 groups: the 
non-cancer and cancer patient groups, to exclude the VEGF 
release from tumor tissues. Interestingly, in non-cancer pa-
tients, higher VEGF levels were found to be a significant 
diagnostic marker for overt DIC. However, this was not 
observed in cancer patients, suggesting that VEGF secreted 
from cancer tissues may obscure the VEGF measurement 
produced by the activation of coagulation. 
  Neutrophils are activated during DIC due to intravascular 
disturbance and formation of cytokines, endotoxins, or 
microclots. Upon stimulation, a neutrophil granule may re-
lease neutrophil elastase. Therefore, neutrophil elastase is 
considered as a marker of neutrophil activation. Neutrophil 
elastase is known to be elevated in severe DIC [6]. Consistent 
with a previous report [6], our data showed that neutrophil 
elastase levels increased depending on the severity of 
coagulopathy. 
  Endostatin is an anti-angiogenic factor. Originally, endo-Korean J Hematol 2010;45:23-8.
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Table 3. Odds ratios of the parameters for the diagnosis of overt DIC.
Cutoff value
a) Odds ratio (95% confidence interval)
Univariate P-value Multivariate
c) P-value
Total patients (n=240)
VEGF (pg/mL) ≤144.4 1
b) ＜0.001 1 0.015
＞144.4 3.67 (2.07-6.51) 2.64 (1.21-5.75)
Endostatin (ng/mL) ≤2.6 1 0.028  1 0.143
＞2.6 2.14 (1.08-4.25) 1.92 (0.80-4.62)
Elastase (ng/mL) ≤144.8 1 ＜0.001 1 0.100
＞144.8 3.32 (1.90-5.81) 1.92 (0.88-4.18)
Platelet (×10
3/μL) ＞80 1 ＜0.001 1 ＜0.001
≤80 16.00 (8.18-31.30) 18.42 (7.89-43.00)
PT (s) ≤20.2 1 ＜0.001 1 ＜0.001
＞20.2 10.28 (5.27-20.06) 7.95 (3.26-19.42)
Fibrinogen (mg/dL) ＞291 1 ＜0.001 1 0.048
≤291 6.41 (3.50-11.75) 2.16 (1.01-4.62)
Cancer patients (n=112)
VEGF (pg/mL) ≤116.2 1 0.003 1 0.513
＞116.2 3.47 (1.51-7.95) 1.54 (0.42-5.67)
Endostatin (ng/mL) ≤5.8 1 0.025 1 0.046
＞5.8 2.81 (1.20-6.60) 5.01 (1.03-24.45)
Elastase (ng/mL) ≤81.2 1 0.014 1 0.098
＞81.2 2.83 (1.25-6.41) 3.34 (0.80-13.94)
Platelet (x10
3/μL) ＞70 1 ＜0.001 1 ＜0.001
≤70 53.60 (16.24-176.91) 96.48 (17.85-521.66)
PT (s) ≤13.9 1 ＜0.001 1 0.001
＞13.9 8.47 (2.73-26.28) 16.95 (3.18-90.34)
Fibrinogen (mg/dL) ＞291 1 ＜0.001 1 0.355
≤291 4.45 (1.92-10.28) 1.86 (0.50-6.94)
Non-cancer patients (n=128)
VEGF (pg/mL) ≤210.2 1 ＜0.001 1 0.005
＞210.2 5.37 (2.37-12.17) 5.62 (1.67-18.89)
Endostatin (ng/mL) ＞8.9 1 0.219 1 0.184
≤8.9 1.76 (0.74-4.18) 0.41 (0.11-1.53)
Elastase (ng/mL) ≤386.7 1 ＜0.001 1 0.017
＞386.7 7.86 (3.23-19.14) 4.42 (1.31-14.88)
Platelet (x10
3/μL) ＞97 1 ＜0.001 1 0.003
≤97 9.40 (3.85-22.97) 5.40 (1.75-16.66)
PT (s) ≤20.2 1 ＜0.001 1 <0.001
＞20.2 16.11 (6.52-39.81) 8.47 (2.86-25.08)
Fibrinogen (mg/dL) ＞220 1 ＜0.001 1 0.015
≤220 11.51 (4.75-27.89) 3.69 (1.29-10.51)
a)Determined as the values yielding the best diagnostic accuracy; 
b)Reference cateory; 
c)Adjusted for age, sex, platelet, PT, and fibrinogen.
Abbreviations: VEGF, vascular endothelial growth factor; PT, prothrombin time.
statin was best known for its antitumor activity in animal 
models [7]. Several studies also showed that the level of 
serum endostatin decreased in some forms of cancers [11, 
12]. However, there have been only a few reports that focused 
on the circulating level of endostatin in benign conditions 
[13]. Because endostatin is a C-terminal fragment of collagen 
type XVIII, endostatin generation is at least partly mediated 
via the activity of protease enzymes such as neutrophil elas-
tase and cathepsin L [7, 8]. In DIC, many serine proteases, 
including factor Xa, thrombin, as well as neutrophil elastase, 
are increased. The circulating endostatin level can be elevated 
due to the active cleavage of serine proteases. However, 
the circulating endostatin level did not increase in severe 
coagulopathy in our study. To verify this assumption, more 
sensitive measurement techniques to detect subtle changes 
in circulating endostatin levels may be required. 
  In conclusion, we showed that the levels of VEGF and 
neutrophil elastase showed a good correlation with the se-
verity of coagulopathy. Furthermore, elevated levels of circu-
lating VEGF and neutrophil elastase were found to be sig-
nificant predictors of overt DIC in non-cancer patients. These 
findings suggest that the levels of circulating VEGF and 
neutrophil elastase are potential diagnostic markers of overt 
DIC, especially in non-cancer patients. Korean J Hematol 2010;45:23-8.
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